Copyright © Inderes 2011 - present. All rights reserved.
  • Uusimmat
  • Pörssi
    • Aamukatsaus
    • Osakevertailu
    • Pörssikalenteri
    • Osinkokalenteri
    • Analyysi
    • Artikkelit
    • Sisäpiirin kaupat
  • inderesTV
  • Mallisalkku
  • Foorumi
  • Premium
  • Femme
  • Opi
    • Sijoituskoulu
    • Q&A
    • Analyysikoulu
  • Meistä
    • Seurantayhtiöt
    • Tiimi
Pörssitiedote

RLS Global AB (publ) Year-end Report, Q4, 2022

RLS Global
Lataa tiedote
OCTOBER 1st - DECEMBER 31st (previous year in brackets)
  • Net sales amounted to TSEK 291 (TSEK 219)
  • Earnings before interest and taxes (EBIT) amounted to MSEK -7,9 (MSEK -7,8)
  • Earnings per share after dilution at SEK -0,10 (SEK 0,09)
  • Cash flow from operating activities amounted to TSEK -5 779 (TSEK -4 887)
  • Liquid assets at the end of the period MSEK 20,5 ( MSEK 11,5)
  • Equity ratio was 83 % (75 %)
JANUARY 1st - DECEMBER 31st (previous year in brackets)
  • Net sales amounted to TSEK 1 198 (TSEK 653)
  • Earnings before interest and taxes (EBIT) amounted to MSEK -24,3 (MSEK 11,0)
  • Earnings per share after dilution at SEK -0,3 (SEK- 0,14)
  • Cash flow from operating activities amounted to TSEK -23 569 (TSEK -8 353)
  • Liquid assets at the end of the period MSEK 20,5 (MSEK 11,5)
  • Equity ratio was 83 % (75 %)
SUMMARY OF EVENTS DURING FIRST QUARTER
  • RLS Global's notified bodies perform quality audits (ISO 13485 and MDD) without remarks
  • Karin Fischer hands in her resignation
  • Convatec is taking over the agreements with Swedish customers
  • ChloraSolv is now delivered to the Convatec central warehouse on a regular basis
  • ChloraSolv is reimbursed in the Netherlands
SUMMARY OF EVENTS DURING SECOND QUARTER
  • Annual General Meeting is held May 19
  • RLS signs distribution contract for Middle East
  • RLS introduces ChloraSolv for the animal segment in Scandinavia by signing distribution contract with Swevet
  • ChloraSolv is approved for leg ulcers in Kuwait
SUMMARY OF EVENTS DURING THIRD QUARTER
  • An article regarding ChloraSolv is published in Journal of Wound Care
  • RLS Global strengthens its solvency by transforming a loan to share capital

 

SUMMARY OF EVENTS DURING FOURTH QUARTER
  • Björn Larsson starts as CEO
  • RLS carries out a new share issue (rights issue) and thereby raises SEK 26.8 million in cash and cash equivalents after issue costs
  • The Swedish Medicines Agency approves RLS' application for a clinical study regarding pressure ulcers
  • RLS takes part in the conference Wounds UK in Harrogate, England
SUMMARY OF EVENTS AFTER FOURTH QUARTER
  • An extra General Meeting is held February 9, 2023
  • Lars Johansson is elected as Chairman of the Board
  • RLS visits Arab Health, a global health conference in the Middle East and performs on-site distributor meetings and training sessions

The Year-end Report Q4, 2022, is enclosed and is also available here. (https://rls.global/wp-content/uploads/2023/02/RLS_Global_Q4_2022_EN.pdf)

Publication
This information was submitted for publication through the agency of the below contact person, at 08.30 CET on Feb 28th 2023.

Sosiaalinen media
  • Inderes Foorumi
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Yhteystiedot
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • Meistä
  • Tiimi
  • Avoimet työpaikat
  • Inderes sijoituskohteena
  • Palvelut pörssiyhtiöille
Sivusto
  • UKK
  • Käyttöehdot
  • Tietosuojaseloste
  • Vastuuvapauslauseke
Inderesin vastuuvapauslauseke löytyy täältä. Kunkin Inderesin aktiivisessa seurannassa olevan osakkeen tarkemmat tiedot löytyvät kunkin osakkeen omilta yhtiösivuilta Inderes-sivustolla. © Inderes Oyj. Kaikki oikeudet pidätetään.